New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
OverviewChart

Quote Panel

Shape
Updated April 26, 2025
1W % 1M % 3M % 1Y %

Key Metrics

Shape

  • Market Cap

  • Shares Outstanding

  • Share in Float

  • Dividende

  • Earning Date

    No Data

  • Price Target

  • Average Volume

  • Beta

  • Range

  • Industry

  • Website

  • Sector

Fundamentals

Shape

Relative Strength

Shape

INZY

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

Analyst rating

Last analyst upgrade/downgrade

Earnings GrowthShape

status-upYoY

Current

Estimates

Q1.23

arrow
arrow

N/A

-0.40
vs -0.71

Q2.23

arrow
arrow

N/A

-0.35
vs -0.38

Q3.23

arrow
arrow

N/A

-0.29
vs -0.38

Q4.23

arrow
arrow

N/A

-0.35
vs -0.42

Q1.24

arrow
arrow

N/A

-0.38
vs -0.40

Q2.24

arrow
arrow

N/A

-0.44
vs -0.35

Q3.24

arrow
arrow

N/A

-0.39
vs -0.29

Q4.24

arrow
arrow

N/A

-0.42
vs -0.35

Q1.25

arrow
arrow

N/A

-0.41
vs -0.38

Q2.25

arrow
arrow

N/A

-0.35
vs -0.44

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

2M  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Q3.24

arrow
arrow

NA

NA  vs NA

Q4.24

arrow
arrow

-100%

NA  vs 2M

Return on EquityShape

status-upQoQ

Q1.23

arrow
arrow

-16%

-0.16
vs -0.16

Q2.23

arrow
arrow

-15%

-0.15
vs -0.16

Q3.23

arrow
arrow

-10%

-0.10
vs -0.15

Q4.23

arrow
arrow

-15%

-0.15
vs -0.10

Q1.24

arrow
arrow

-20%

-0.20
vs -0.15

Q2.24

arrow
arrow

-29%

-0.29
vs -0.20

Q3.24

arrow
arrow

-30%

-0.30
vs -0.29

Q4.24

arrow
arrow

-47%

-0.47
vs -0.30

Institutionnal OwnershipShape

status-upQoQ

Q1.23

arrow
arrow

53

53
vs 36

47%

Q2.23

arrow
arrow

77

77
vs 53

45%

Q3.23

arrow
arrow

82

82
vs 77

6%

Q4.23

arrow
arrow

84

84
vs 82

2%

Q1.24

arrow
arrow

91

91
vs 84

8%

Q2.24

arrow
arrow

92

92
vs 91

1%

Q3.24

arrow
arrow

90

90
vs 92

-2%

Q4.24

arrow
arrow

105

105
vs 90

17%

Earnings Growth

Latest News

INZY

globenewswire.com

8 hours ago

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
INZY

globenewswire.com

8 hours ago

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
INZY

globenewswire.com

8 hours ago

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
INZY

globenewswire.com

8 hours ago

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
INZY

globenewswire.com

8 hours ago

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
INZY

globenewswire.com

8 hours ago

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference